-
Article
Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells
This study investigated the development of peripheral blood natural killer (NK) and lymphokineactivated killer (LAK) cell activity in vivo in cancer patients treated with high doses of recombinant interleukin-...
-
Chapter and Conference Paper
Evaluation of In Vivo Natural Killer and Lymphokine-Activated Killer Cell Activity in Patients Treated with High-Dose Interleukin-2 and Adoptive Transfer of Autologous LAK Cells
A substantial number of Phase I and Phase II clinical trials of interleukin-2 (IL-2) alone or combined with adoptive transfer of lymphokine-activated killer (LAK) cells in the treatment of cancer patients had ...
-
Article
CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma
Patients with recurrent or refractory Hodgkin's and non-Hodgkin's lymphoma are increasingly being treated with high-dose therapy and hematopoietic cell transplantation. As minimal disease status at the time of...
-
Article
Rituximab (Mabthera™, rituxan™) in patients with recurrent indolent lymphoma
The objective of this multiinstitutional study was to evaluate the safety and efficacy of rituximab at standard four weekly doses in patients with recurrent indolent lymphoma. Thirty-eight patients entered int...
-
Article
Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma
Follicular Lymphoma International Prognostic Index—FLIPI is an established clinical predictor for outcome in follicular lymphoma. The role of molecular abnormalities in blood and bone marrow of follicular lymp...
-
Article
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials